APRIL:TACI axis is dispensable for the immune response to rabies vaccination

被引:3
|
作者
Haley, Shannon L. [1 ]
Tzvetkov, Evgeni P. [1 ]
Lytle, Andrew G. [1 ]
Alugupalli, Kishore R. [1 ]
Plummer, Joseph R. [1 ]
McGettigan, James P. [1 ,2 ]
机构
[1] Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Vaccine Ctr, Philadelphia, PA 19107 USA
基金
美国国家卫生研究院;
关键词
Rabies; Vaccine; APRIL; TACI; Antibody; NECROSIS-FACTOR FAMILY; B-CELL; PLASMA-CELLS; VIRUS; BAFF; TACI; INFECTION; VACCINES; RECEPTOR; BCMA;
D O I
10.1016/j.antiviral.2017.06.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is significant need to develop a single-dose rabies vaccine to replace the current multi-dose rabies vaccine regimen and eliminate the requirement for rabies immune globulin in post-exposure settings. To accomplish this goal, rabies virus (RABV)-based vaccines must rapidly activate B cells to secrete antibodies which neutralize pathogenic RABV before it enters the CNS. Increased understanding of how B cells effectively respond to RABV-based vaccines may improve efforts to simplify post-exposure prophylaxis (PEP) regimens. Several studies have successfully employed the TNF family cytokine a proliferation-inducing ligand (APRIL) as a vaccine adjuvant. APRIL binds to the receptors TACI and B cell maturation antigen (BCMA) expressed by B cells in various stages of maturation with high affinity. We discovered that RABV-infected primary murine B cells upregulate APRIL ex vivo. Cytokines present at the time of antigen exposure affect the outcome of vaccination by influencing T and B cell activation and GC formation. Therefore, we hypothesized that the presence of APRIL at the time of RABV-based vaccine antigen exposure would support the generation of protective antibodies against RABV glycoprotein (G). In an effort to improve the response to RABV vaccination, we constructed and characterized a live recombinant RABV-based vaccine vector which expresses murine APRIL (rRABV-APRIL). lmmunogenicity testing in mice demonstrated that expressing APRIL from the RABV genome does not impact the primary antibody response against RABV G compared to RABV alone. In order to evaluate the necessity of APRIL for the response to rabies vaccination, we compared the responses of APRIL-deficient and wild-type mice to immunization with rRABV. APRIL deficiency does not affect the primary antibody response to vaccination. Furthermore, APRIL expression by the vaccine did not improve the generation of long-lived antibody-secreting plasma cells (PCs) as serum antibody levels were equivalent in response to rRABV-APRIL and the vector eight weeks after immunization. Moreover, APRIL is dispensable for the long-lived antibody-secreting PC response to rRABV vaccination as anti-RABV G IgG levels were similar in APRIL-deficient and wild-type mice six months after vaccination. Mice lacking the APRIL receptor TACI demonstrated primary anti-RABV G antibody responses similar to wild-type mice following immunization with the vaccine vector indicating that this response is independent of TACI-mediated signals. Collectively, our findings demonstrate that APRIL and associated TACI signaling is dispensable for the immune response to RABV-based vaccination. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 50 条
  • [21] IMMUNE-REACTIONS AGAINST RABIES VIRUSES - INFECTION AND VACCINATION
    SUSS, J
    SINNECKER, H
    EXPERIMENTAL PATHOLOGY, 1991, 42 (01): : 1 - 9
  • [22] Assessment of Immune Responses to Rabies Vaccination in Free-Ranging Dogs in Bengaluru, India
    Rao, Vinay Chavan Prakash
    Ramakrishnaiah, Sharada
    Isloor, Shrikrishna
    Doddamane, Rathnamma
    Lakshman, Dilip
    Maralavadi, Manjunath Shinde Sundar Rao
    Bhat, Avinash
    Chandrashekar, Balaji
    Natesan, Krithiga
    Kondabattula, Ganesh
    Hegde, Nagendra R.
    VACCINES, 2023, 11 (05)
  • [23] Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man
    Brinkman, DMC
    Jol-Van der Zijde, CM
    Ten Dam, MM
    Vossen, JM
    Osterhaus, ADME
    Kroon, FP
    Van Tol, MJD
    JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (06) : 528 - 538
  • [24] Immune response to influenza vaccination in an elderly population
    Brydak, LB
    Machala, M
    Mysliwska, J
    Mysliwski, A
    Trzonkowski, P
    JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (03) : 214 - 222
  • [25] Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant
    Trakarnvanich, Thananda
    Ngamvichchukorn, Tanun
    Phumisantiphong, Uraporn
    Pholtawornkulchai, Kittisak
    Phochanasomboon, Krittima
    Manomaipiboon, Anan
    VACCINE, 2022, 40 (45) : 6499 - 6511
  • [26] Factors influencing the antibody response to vaccination against rabies
    Jakel, V.
    Koenig, M.
    Cussler, K.
    Hanschmann, K.
    Thiel, H. -J.
    TOWARDS THE ELIMINATION OF RABIES IN EURASIA, 2008, 131 : 431 - 437
  • [27] Immune response following postexposure rabies prophylaxis
    Gozdas, Hasan Tahsin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1878 - 1878
  • [28] Immune response in cattle vaccinated against rabies
    de Oliveira, AN
    Andrade, MCR
    da Silva, MV
    de Moura, WC
    Contreiras, EC
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2000, 95 (01): : 83 - 88
  • [29] Evaluation of Bait Acceptance and Immune Response in Local Dogs during an Oral Rabies Vaccination Field Study in Morocco
    Aboulfidaa, Nadia
    Cliquet, Florence
    Robardet, Emmanuelle
    Darkaoui, Sami
    Wasniewski, Marine
    Kaiser, Christian
    Bobe, Katharina
    Vos, Ad
    Fihri, Ouafaa Fassi
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2024, 9 (07)
  • [30] Humoral Immune Response of Thai Dogs after Oral Vaccination against Rabies with the SPBN GASGAS Vaccine Strain
    Leelahapongsathon, Kansuda
    Kasemsuwan, Suwicha
    Pinyopummintr, Tanu
    Boodde, Orawan
    Phawaphutayanchai, Parinya
    Aiyara, Nirut
    Bobe, Katharina
    Vos, Ad
    Friedrichs, Virginia
    Muller, Thomas
    Freuling, Conrad M.
    Chanachai, Karoon
    VACCINES, 2020, 8 (04) : 1 - 14